1. Home
  2. ONIT vs NMRA Comparison

ONIT vs NMRA Comparison

Compare ONIT & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ONIT
  • NMRA
  • Stock Information
  • Founded
  • ONIT 1988
  • NMRA 2019
  • Country
  • ONIT United States
  • NMRA United States
  • Employees
  • ONIT N/A
  • NMRA N/A
  • Industry
  • ONIT
  • NMRA
  • Sector
  • ONIT
  • NMRA
  • Exchange
  • ONIT NYSE
  • NMRA Nasdaq
  • Market Cap
  • ONIT N/A
  • NMRA 287.6M
  • IPO Year
  • ONIT 1996
  • NMRA 2023
  • Fundamental
  • Price
  • ONIT $32.32
  • NMRA $1.01
  • Analyst Decision
  • ONIT Buy
  • NMRA Buy
  • Analyst Count
  • ONIT 1
  • NMRA 8
  • Target Price
  • ONIT $45.00
  • NMRA $10.14
  • AVG Volume (30 Days)
  • ONIT 39.4K
  • NMRA 1.2M
  • Earning Date
  • ONIT 05-01-2025
  • NMRA 03-03-2025
  • Dividend Yield
  • ONIT N/A
  • NMRA N/A
  • EPS Growth
  • ONIT N/A
  • NMRA N/A
  • EPS
  • ONIT 4.13
  • NMRA N/A
  • Revenue
  • ONIT $976,000,000.00
  • NMRA N/A
  • Revenue This Year
  • ONIT $8.40
  • NMRA N/A
  • Revenue Next Year
  • ONIT $13.89
  • NMRA N/A
  • P/E Ratio
  • ONIT $7.89
  • NMRA N/A
  • Revenue Growth
  • ONIT N/A
  • NMRA N/A
  • 52 Week Low
  • ONIT $22.40
  • NMRA $0.95
  • 52 Week High
  • ONIT $41.27
  • NMRA $17.19
  • Technical
  • Relative Strength Index (RSI)
  • ONIT 51.18
  • NMRA 26.42
  • Support Level
  • ONIT $32.21
  • NMRA $1.12
  • Resistance Level
  • ONIT $35.71
  • NMRA $1.23
  • Average True Range (ATR)
  • ONIT 1.41
  • NMRA 0.10
  • MACD
  • ONIT 0.25
  • NMRA 0.04
  • Stochastic Oscillator
  • ONIT 48.40
  • NMRA 2.18

About NMRA Neumora Therapeutics Inc.

Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has rapidly scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. The company expects to continue to progress in the development of its pipeline with the planned initiation of multiple clinical trials across its programs over the next 12 to 18 months, which supports numerous anticipated data readouts.

Share on Social Networks: